Experts provide a review of therapeutic interventions for NAFLD/NASH, including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).

What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.

Experts provide a review of genetic causes of obesity, the utility of genetic testing, and evidence for and appropriate use of medications for the treatment of genetic obesity disorders.